Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study

Amonafide 300 mg/M2 was administeredintravenously on a daily × 5 schedule to 27eligible patients with recurrent orprogressive central nervous system tumors. There were no objective responses. Themost common toxicities weregastrointestinal, hematologic andneurologic. Further study of amonafide inpatients with central nervous systemmalignancies is not indicated.